One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Caribou Biosciences, Inc.
CRBU · NMS · Healthcare · Biotechnology
Current price
$0.41
52-week range
$0.40 - $2.49
Market cap
$44.20M
Balance sheet
Healthy
-17,024.25x Concerning
Net cash $68.46M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Operating margin compressed from -768.2% to -1720.1% over 3 years.
- Risk Return on equity was -93.8% last year — the company lost money on shareholders' equity.
What this company does
Caribou Biosciences, Inc.
Caribou Biosciences is a company developing a cutting-edge technology called CRISPR to edit genes, with the goal of creating new treatments for serious diseases like certain types of blood cancer. Their main income and progress come from developing these experimental therapies, which are still in early testing stages, meaning their success depends on proving these treatments can work safely and effectively in people. This matters because if their gene-editing therapies prove successful, they could offer entirely new ways to fight illnesses that currently have limited treatment options.
How the company got here
Caribou Biosciences was founded in 2011 by leading scientists in the field of CRISPR gene-editing technology, including Nobel laureate Jennifer Doudna. The company aimed to use this groundbreaking technology to develop "off-the-shelf" cell therapies for serious diseases. Caribou went public in July 2021, raising over $300 million. However, despite early promise and significant investment, the company has faced challenges. In October 2026, Caribou announced it was discontinuing its two main clinical programs and undertaking significant workforce reductions due to difficulties in securing the necessary funding in the current financial climate for this type of therapy. The company is now exploring strategic alternatives, such as a merger or sale.
What it actually does
Caribou Biosciences is a biotechnology company that uses a powerful gene-editing tool called CRISPR. Think of CRISPR like a highly precise pair of molecular scissors that can find and change specific parts of DNA, the instruction manual for our bodies. Caribou's goal was to use this technology to create "allogeneic" cell therapies. "Allogeneic" means that the cells come from a healthy donor, rather than being taken from the patient themselves. These donor cells are then genetically edited using CRISPR to become "CAR-T" cells, which are designed to attack cancer cells. The idea is to create "off-the-shelf" treatments that can be readily available for patients, similar to how you might pick up a medicine from a pharmacy.
Allogeneic CAR-T Cell Therapies
Caribou's primary focus was on developing allogeneic CAR-T cell therapies. CAR-T stands for Chimeric Antigen Receptor T-cell. T-cells are a type of white blood cell that helps fight infections, and CAR is a special protein that scientists engineer onto these T-cells to help them recognize and attack cancer cells. In Caribou's case, they were developing these CAR-T cells from healthy donors (allogeneic) and using CRISPR to edit them. The company had two main programs in this area: vispacabtagene regedleucel (vispa-cel) for certain types of lymphoma, and CB-011 for multiple myeloma, a type of blood cancer. These therapies were in clinical trials, meaning they were being tested in patients to see if they were safe and effective.
What management is betting on now
Following a strategic review in October 2026, Caribou Biosciences decided to discontinue its two main CAR-T cell therapy programs, vispa-cel and CB-011. This decision was driven by the challenging financial environment for developing allogeneic CAR-T therapies, making it difficult to secure the capital needed for further development. The company is now exploring strategic alternatives, which could include a merger, acquisition, or other business combination, to maximize value for its stockholders. The remaining assets include the company's CRISPR genome-editing platform, clinical data from its past programs, and its cash reserves.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-35.99M
FY2025 Q1
$-37.77M
FY2025 Q2
$-28.68M
FY2025 Q3
$-25.30M
FY2025 Q4
$-21.04M
FY2026 Q1
$-27.06M
FY2026 Q2
$-22.79M
FY2026 Q3
$-22.54M
Revenue
$1.61M
Net income
$-26.61M
Diluted EPS
-0.25
Operating cash flow
$-22.52M
Free cash flow
$-22.54M
Fetching…
Sources
Revenue
$1.50M
Net income
$-24.28M
Diluted EPS
-0.24
Operating cash flow
$-22.79M
Free cash flow
$-22.79M
Fetching…
Sources
Revenue
$2.40M
Net income
$-25.09M
Diluted EPS
-0.26
Operating cash flow
$-26.98M
Free cash flow
$-27.06M
Fetching…
Sources
Revenue
$3.94M
Net income
$-26.49M
Diluted EPS
-0.28
Operating cash flow
$-20.82M
Free cash flow
$-21.04M
Fetching…
Sources
Revenue
$2.20M
Net income
$-27.55M
Diluted EPS
-0.30
Operating cash flow
$-25.18M
Free cash flow
$-25.30M
Fetching…
Sources
Revenue
$2.67M
Net income
$-54.10M
Diluted EPS
-0.58
Operating cash flow
$-28.26M
Free cash flow
$-28.68M
Fetching…
Sources
Revenue
$2.35M
Net income
$-39.99M
Diluted EPS
-0.43
Operating cash flow
$-36.73M
Free cash flow
$-37.77M
Fetching…
Sources
Revenue
$2.08M
Net income
$-35.49M
Diluted EPS
-0.39
Operating cash flow
$-35.47M
Free cash flow
$-35.99M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.41
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $68.5M - more cash than debt. Interest coverage -17024.2x.
Net debt
$-68.46M
Interest coverage
-17,024.25x
Caribou Biosciences, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
CRBU
BASELINE
Caribou Biosciences, Inc.
Total debt $26.34M Interest coverage -17,024.25x This is the baseline the peer rows are being compared against.
Total debt $27.72M Interest coverage -36.67x Neither company has much profit cushion over interest right now.
Total debt $15.51M Interest coverage -16.10x Neither company has much profit cushion over interest right now.
Total debt $9.88M Interest coverage 9.46x This peer still has a real interest-payment cushion, while CRBU does not.
Total debt — Interest coverage -192.50x Neither company has much profit cushion over interest right now.
What you should know
The case for and against CRBU
0 Rewards
2 Risks
Rewards
Risks
-
Operating margin compressed from -768.2% to -1720.1% over 3 years.
-
Return on equity was -93.8% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.46x
P/B
0.58x
P/S
4.68x
EV/EBITDA
0.23x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
-1,720.1%
Net margin
0.0%
ROE
-93.8%
ROA
-41.4%
Health
Liquidity and balance-sheet strength
Debt / equity
0.34x
Current ratio
4.97x
Quick ratio
4.79x
Total debt
$26.34M
Total cash
$94.80M
Growth
How the business has been compounding
Revenue TTM
$9.44M
Revenue 5Y CAGR
3.8%
EPS TTM
-1.08
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-93.11M
Free CF TTM
$-112.35M
FCF margin
-1,189.7%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—